JP2023536921A - 心障害およびうっ血性心不全を処置する方法ならびにａａｖベクターを投与する方法 - Google Patents

心障害およびうっ血性心不全を処置する方法ならびにａａｖベクターを投与する方法 Download PDF

Info

Publication number
JP2023536921A
JP2023536921A JP2023507620A JP2023507620A JP2023536921A JP 2023536921 A JP2023536921 A JP 2023536921A JP 2023507620 A JP2023507620 A JP 2023507620A JP 2023507620 A JP2023507620 A JP 2023507620A JP 2023536921 A JP2023536921 A JP 2023536921A
Authority
JP
Japan
Prior art keywords
cardiomyopathy
heart
seq
heart failure
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536921A5 (https=
Inventor
マイケル ダブリュー． オカラガン，
マイケル エル． ロバーツ，
ジョージ オマル ヤネス－クーナ，
ゴンザレス， フアン マヌエル イグレシアス
アントニア エブリピオティ，
シンクレア クーパー，
フェルジン セスナ，
ロジャー ハジャル，
アンナ トレチャコヴァ，
Original Assignee
アスクレピオス バイオファーマシューティカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスクレピオス バイオファーマシューティカル， インコーポレイテッド filed Critical アスクレピオス バイオファーマシューティカル， インコーポレイテッド
Publication of JP2023536921A publication Critical patent/JP2023536921A/ja
Publication of JP2023536921A5 publication Critical patent/JP2023536921A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023507620A 2020-08-05 2021-08-05 心障害およびうっ血性心不全を処置する方法ならびにａａｖベクターを投与する方法 Pending JP2023536921A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063061342P 2020-08-05 2020-08-05
US63/061,342 2020-08-05
US202163214119P 2021-06-23 2021-06-23
US63/214,119 2021-06-23
PCT/US2021/044650 WO2022031914A2 (en) 2020-08-05 2021-08-05 Methods of treating cardiac disorders and congestive heart failure and administering aav vectors

Publications (2)

Publication Number Publication Date
JP2023536921A true JP2023536921A (ja) 2023-08-30
JP2023536921A5 JP2023536921A5 (https=) 2024-08-13

Family

ID=80120133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507620A Pending JP2023536921A (ja) 2020-08-05 2021-08-05 心障害およびうっ血性心不全を処置する方法ならびにａａｖベクターを投与する方法

Country Status (8)

Country Link
US (1) US20230340528A1 (https=)
EP (1) EP4192580A4 (https=)
JP (1) JP2023536921A (https=)
CN (1) CN116406297A (https=)
AU (1) AU2021320244A1 (https=)
CA (1) CA3188398A1 (https=)
IL (1) IL300367A (https=)
WO (1) WO2022031914A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
BR112023006305A2 (pt) 2020-10-09 2023-05-09 Tenaya Therapeutics Inc Métodos e composições de terapia gênica com placofilina-2
AU2022297795A1 (en) * 2021-06-23 2024-01-04 AskBio Inc. Regulatory nucleic acid sequences
WO2023178338A2 (en) * 2022-03-18 2023-09-21 University Of Florida Research Foundation, Incorporated Methods and compositions for treating tmem43 related cardiomyopathy with a viral vector
JP2025512405A (ja) * 2022-04-11 2025-04-17 テナヤ セラピューティクス， インコーポレイテッド プラコフィリン２遺伝子治療の処置の方法
CN116256523B (zh) * 2023-02-02 2023-09-12 香港大学深圳医院 生物标志物在制备用于糖尿病患者HFpEF检测试剂中的应用
IL322735A (en) * 2023-02-13 2025-10-01 Astrazeneca Ireland Ltd Nucleic acids encoding BCL2-associated athenogen 3 (BAG3) for gene therapy
CN116644347B (zh) * 2023-05-23 2025-11-28 珠海市康利莱医疗器械有限公司 一种用于风湿性瓣膜病的血清差异多肽检测系统
EP4719440A1 (en) * 2023-06-01 2026-04-08 Alkahest, Inc. Compositions of blood plasma fractions and blood plasma subfractions and their use in treatment of disease
TW202525313A (zh) * 2023-09-06 2025-07-01 瑞士商迪納柯公司 用ａａｖ基因治療載體及治療調配物治療肥厚性心肌病之方法
WO2025259575A1 (en) * 2024-06-10 2025-12-18 Asklepios Biopharmaceutical, Inc. Methods and compositions for treatment of duchenne muscular dystrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056539B (zh) * 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
BRPI0912559A2 (pt) * 2008-05-16 2015-10-13 Corthera Inc método de tratar insuficiência cardíaca crônica
EP4081643A1 (en) * 2019-12-24 2022-11-02 Asklepios Biopharmaceutical, Inc. Regulatory nucleic acid sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY, vol. 22, no. 12, JPN6025031634, 2014, pages 2038 - 2045, ISSN: 0005654717 *

Also Published As

Publication number Publication date
AU2021320244A1 (en) 2023-03-23
IL300367A (en) 2023-04-01
WO2022031914A2 (en) 2022-02-10
CN116406297A (zh) 2023-07-07
CA3188398A1 (en) 2022-02-10
WO2022031914A3 (en) 2022-03-31
EP4192580A2 (en) 2023-06-14
EP4192580A4 (en) 2025-06-18
US20230340528A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
JP2023536921A (ja) 心障害およびうっ血性心不全を処置する方法ならびにａａｖベクターを投与する方法
JP6793758B2 (ja) 最適化されたミニ−ジストロフィン遺伝子および発現カセットおよびそれらの使用
US20240042060A1 (en) Optimized expression cassettes for gene therapy
US12564647B2 (en) Optimized expression cassettes for gene therapy
US20160166651A1 (en) Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
CN114521143B (zh) 减轻fkrp心脏毒性的基因治疗表达系统
US20200308582A1 (en) Kcnk3-based gene therapy of cardiac arrhythmia
WO2021021021A1 (en) Treatment of dilated cardiomyopathy and/or cardiac fibrosis
TW202117017A (zh) 人類心肌病的ａａｖ心臟基因療法
JP2021020890A (ja) Ａａｖミニジストロフィン遺伝子治療を使用してデュシェンヌ型筋ジストロフィーを処置する方法
Greer-Short et al. Gene Therapy Mediates Therapeutic Improvement in Cardiac Hypertrophy and Survival in a Murine Model of MYBPC3-Associated Cardiomyopathy
ES2975422T3 (es) Proteínas con actividad cardioprotectora
HK40090887A (zh) 治疗心贜疾患和充血性心力衰竭以及施用aav载体的方法
US20220364090A1 (en) Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128
KR20250169529A (ko) 유전자 요법을 위한 Bcl2-관련 아타노진 3(BAG3)을 인코딩하는 핵산
Paldino TITIN DOWNREGULATION AFFECTS CARDIOMYOCYTES PROLIFERATION
WO2024259197A2 (en) ELIMINATION OF CAMKIIδ AUTOPHOSPHORYLATION BY CRISPR-CAS9 GENE EDITING IMPROVES CARDIAC FUNCTION IN HEART FAILURE
TW202525313A (zh) 用ａａｖ基因治療載體及治療調配物治療肥厚性心肌病之方法
TW202242120A (zh) 用於心臟基因療法之載體的增加之包裝效率
EA048262B1 (ru) Повышенная эффективность упаковки вектора для генотерапии сердечных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202